Skip to main content
Representatives urge end to DIR fees

The CMS should end direct and indirect remuneration fees, since beneficiaries often don't see cost benefits and DIR fees can lead to negative reimbursement for pharmacies, wrote more than 50 members of Congress in a letter to HHS and the CMS. "We also urge CMS to ensure patient access to specialty pharmacies is not limited by the use of inapplicable Star Rating measures," they wrote.

Full Story: